Episurf Medical AB (publ) held an Extraordinary General Meeting in Stockholm today 22 May 2024 at which it was resolved, among other things, to approve the Board of Directors' resolution on a rights issue of units.
The Extraordinary General Meeting resolved, in accordance with the Board of Directors' proposal, to approve the Board of Directors' resolution of 22 April 2024 to issue units consisting of shares of series B and warrants of series TO13 B with preferential rights for existing shareholders (the "Rights Issue").
In order to enable the execution of the Rights Issue, the Extraordinary General Meeting also resolved, in accordance with the Board of Directors' proposal, to reduce the share capital limits in the Articles of Association and to reduce the share capital in order to reduce the quota value of the shares, and to increase the limits for the number of shares in the Articles of Association.
In order to ensure that the company may execute the above-mentioned resolution to reduce the share capital without approval from the Swedish Companies Registration Office or public court, the Extraordinary General Meeting further resolved, in accordance with the Board of Directors' proposal, to increase the share capital limits in the Articles of Association and on a bonus issue which, together with the Rights Issue, results in neither the company's restricted equity nor its share capital being reduced.
In order to reduce the quota value of the company's shares after the completion of the Rights Issue, the Extraordinary General Meeting finally resolved, in accordance with the Board of Directors' proposal, to reduce the share capital limits in the Articles of Association and to reduce the share capital subject to approval from the Swedish Companies Registration Office or public court.
For further information on the proposals that have now been approved by the Extraordinary General Meeting, see the information in the notice of the Extraordinary General Meeting published on 22 April 2024.
Episurf Medical AB (publ)
The Board of Directors
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 10.00 CEST on 22 May 2024.
